ICD-10 category · Chapter XXII · U50
U50 Drug resistant tuberculosis
25 codes under U50 in the South African Master Industry Table 2021, 16 valid for clinical use; 6 marked as a Prescribed Minimum Benefit.
| Code | Description | Use | Benefits |
|---|---|---|---|
| U50 | Drug resistant tuberculosis | Heading only | — |
| U50.0 | Multidrug resistant tuberculosis (MDR TB) | Heading only | — |
| U50.00 | Primary multidrug resistant tuberculosis (MDR TB) | Valid · not as primary | — |
| U50.01 | Secondary multidrug resistant tuberculosis (MDR TB) | Valid · not as primary | — |
| U50.1 | Drug resistant tuberculosis, resistance to isoniazid (INH) only | Heading only | — |
| U50.10 | Drug resistant tuberculosis, primary resistance to isoniazid (INH) only | Valid · not as primary | PMB 11S Tuberculosis · Diagnosis and acute medical management; successful transfer to maintenance therapy in accordance to DOH guidelines |
| U50.11 | Drug resistant tuberculosis, secondary resistance to isoniazid (INH) only | Valid · not as primary | — |
| U50.2 | Drug resistant tuberculosis, resistance to rifampicin only | Heading only | — |
| U50.20 | Drug resistant tuberculosis, primary resistance to rifampicin only | Valid · not as primary | — |
| U50.21 | Drug resistant tuberculosis, secondary resistance to rifampicin only | Valid · not as primary | — |
| U50.3 | Drug resistant tuberculosis, resistance to isoniazid (INH) and rifampicin and any other anti-tuberculosis drug | Heading only | — |
| U50.30 | Drug resistant tuberculosis, primary resistance to isoniazid (INH) and rifampicin and any other anti-tuberculosis drug | Valid · not as primary | PMB 11S Tuberculosis · Diagnosis and acute medical management; successful transfer to maintenance therapy in accordance to DOH guidelines |
| U50.31 | Drug resistant tuberculosis, secondary resistance to isoniazid (INH) and rifampicin and any other anti-tuberculosis drug | Valid · not as primary | — |
| U50.4 | Drug resistant tuberculosis, resistance to isoniazid (INH) and rifampicin and any drug not classified as an anti-tuberculosis drug, including antibiotics, anti-leprotics, etc | Heading only | — |
| U50.40 | Drug resistant tuberculosis, primary resistance to isoniazid (INH) and rifampicin and any drug not classified as an anti-tuberculosis drug, including antibiotics, anti-leprotics, etc | Valid · not as primary | PMB 11S Tuberculosis · Diagnosis and acute medical management; successful transfer to maintenance therapy in accordance to DOH guidelines |
| U50.41 | Drug resistant tuberculosis, secondary resistance to isoniazid (INH) and rifampicin and any drug not classified as an anti-tuberculosis drug, including antibiotics, anti-leprotics, etc | Valid · not as primary | — |
| U50.5 | Extensively drug resistant tuberculosis (XDR TB), resistance to INH and rifampicin, and any fluoroquinolone plus capreomycin and/or kanamicin and/or amikacin | Heading only | — |
| U50.50 | Extensively drug resistant tuberculosis, primary resistance to INH and rifampicin, and any fluoroquinolone plus capreomycin and/or kanamicin and/or amikacin | Valid · not as primary | PMB 11S Tuberculosis · Diagnosis and acute medical management; successful transfer to maintenance therapy in accordance to DOH guidelines |
| U50.51 | Extensively drug resistant tuberculosis, secondary resistance to isoniazid and rifampicin, and any fluoroquinolone plus one of: capreomycin and/or kanamicin and/or amikacin | Valid · not as primary | — |
| U50.6 | Extensively drug resistant tuberculosis (XDR TB), resistance to INH and rifampicin, and any fluoroquinolone plus other specified second-line injectable anti-TB drug | Heading only | — |
| U50.60 | Extensively drug resistant tuberculosis, primary resistance to INH and rifampicin, and any fluoroquinolone plus other specified second-line injectable anti-TB drug | Valid · not as primary | PMB 11S Tuberculosis · Diagnosis and acute medical management; successful transfer to maintenance therapy in accordance to DOH guidelines |
| U50.61 | Extensively drug resistant tuberculosis, secondary resistance to INH and rifampicin, and any fluoroquinolone plus other specified second-line injectable anti-TB drug | Valid · not as primary | — |
| U50.9 | Drug resistant tuberculosis, drug unspecified | Heading only | — |
| U50.90 | Drug resistant tuberculosis, primary resistance to drug, unspecified | Valid · not as primary | PMB 11S Tuberculosis · Diagnosis and acute medical management; successful transfer to maintenance therapy in accordance to DOH guidelines |
| U50.91 | Drug resistant tuberculosis, secondary resistance to drug, unspecified | Valid · not as primary | — |
Prescribed Minimum Benefits in U50. A medical scheme must fund the diagnosis, treatment and care of a PMB condition in full, within its rules on designated providers and treatment protocols. The PMB code and treatment component beside each code come from the Council for Medical Schemes’ PMB Coded List; the scheme decides whether a given claim qualifies.
Source and terms
Reproduced from the national table, unaltered.
The Department publishes the table for the industry to load. The ICD-10 Master Industry Table page
Codes and descriptions: ICD-10 Master Industry Table (MIT) 2021, published 16 March 2021 by the National Department of Health, Republic of South Africa. ® National Department of Health: all rights reserved. Reproduced for reference without alteration.
ICD-10 is the International Statistical Classification of Diseases and Related Health Problems, Tenth Revision, © World Health Organization. The WHO ICD-10 descriptions appear as published in the MIT.
Prescribed Minimum Benefit (PMB) and Chronic Disease List (CDL) markers: Council for Medical Schemes, PMB Coded List, as read by GreenNotes. Benefit decisions rest with each medical scheme.
Source file: ICD-10_MIT_2021_Excel_16-March_2021.xlsx. Found an error in a code or description? Write to help@greennotes.co.za.
This lookup is a reference to the published code table, not coding advice. Code assignment is the treating practitioner’s responsibility, following the South African ICD-10 Coding Standards and Guidelines and the WHO ICD-10 volumes. GreenNotes does not warrant that the table is complete or current.
This is the South African table. Most ICD-10 results online are the United States’ ICD-10-CM, a different code set that South African medical schemes do not accept. Regulation 5 of the General Regulations under the Medical Schemes Act requires the diagnostic code on every account, and the Master Industry Table is the list it is coded from.
In GreenNotes
Code the consultation once. The invoice and the claim pick it up.
GreenNotes looks codes up from this same table while you write the consultation. The codes you record there, including any the clinical AI included for your review, carry into the invoice and the medical-aid claim.